Trastuzumab Emtansine (T-DM1) increases progression-free survival (PFS) in metastatic breast cancer patients compared to patients who received lapatinib (Tykerb;
GlaxoSmithKline Plc) and
capecitabine (Xeloda; Roche) combination, Roche made the announcement today in a press release. The overall surivival (OS) data is not mature yet.
Oncology targets, strategies, cancer drug development and personalized medicine
Showing posts with label xeloda. Show all posts
Showing posts with label xeloda. Show all posts
Subscribe to:
Posts (Atom)